Skip to main content

Early Antibiotics for COVID-19 Can Cut Recovery Time

Medically reviewed by Carmen Pope, BPharm. Last updated on March 25, 2024.

By Lori Solomon HealthDay Reporter

MONDAY, March 25, 2024 -- A significant reduction in recovery time is seen among COVID-19 patients who receive early antibiotic treatment, according to a study published online March 20 in the Journal of Medical Virology.

Carlo Brogna, M.D., from the Craniomed Group Srl. Research Facility in Bresso, Italy, and colleagues studied the impact of specific antibiotics on recovery from COVID-19. The analysis included 211 COVID-19 patients (59 vaccinated).

The researchers found that early initiation of antibiotic therapy resulted in a significantly shorter recovery time (crude hazard ratio [HR], 4.74). Simultaneous use of nonsteroidal anti-inflammatory drugs did not shorten duration and in a multivariate analysis prolonged the disease. Longer recovery time was also seen in a subgroup of 42 patients receiving corticosteroids for a median of three days (crude HR, 0.542). Early initiation of antibiotics was associated with maintaining higher levels of blood oxygen saturation. Furthermore, a significant number of patients who received antibiotics in the first three days of acute illness for a duration of seven days did not develop long COVID.

"The gut microbiome's bacterial composition is highly dynamic, capable of producing proteins that interact with host cells, potentially triggering detrimental mechanisms," the authors write. "This discovery implies a potential correlation between long COVID and a bacterial by-product within the microbiome, suggesting potential treatment alterations involving antibiotics and probiotics."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

Further Support and Information on COVID-19

Read this next

Higher COVID-19 Vaccination Rates Tied to Decrease in Childhood Asthma Symptoms

WEDNESDAY, July 3, 2024 -- Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter...

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.